Navigating regulatory fragmentation in the convergence of synthetic biology, artificial intelligence, and automation

Convergent technologies, divergent governance

The convergence of synthetic biology (SynBio), artificial intelligence (AI) and automation—referred to as SynBioxAI—represents one of the most consequential developments in contemporary life sciences^1,2,3. AI systems now propose hypotheses and designs; robotic, high-throughput, fully autonomous, AI-driven biofoundries execute them; engineering biology platforms translate them into biological function⁴. The design–build–test–learn cycle that once took months can increasingly be completed in days, and the frontier is moving toward closed-loop systems in which AI directs automated experimentation with diminishing human intervention^5,6. In its November 2025 Science, Technology and Industry Policy Paper No 187², the forward-looking technology assessment the Organisation for Economic Co-operation and Development (OECD) identified this convergence in SynBioxAI as a domain of transformative potential—for drug discovery, biomanufacturing, environmental remediation and agriculture—but one where governance, safety and strategic intelligence lag the pace of technical capability². As noted above, the driving force behind this convergence is the rapid advance in AI and the integration of these capabilities with SynBio. Logically, this would lead to adoption of AIxSynBio as the descriptive shorthand; however, in this paper we have adopted SynBioxAI for consistency with the OECD nomenclature.